Value through InnovationApril 24 2015

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim press releases. To quickly find all press releases on a specific topic, please use the search.

Press Release Archive

back 1 2 3 4 5 6 7 8 9 10
04.23.2015

FDA Grants Priority Review to Boehringer Ingelheim’s Biologics License Application for Idarucizumab*

04.22.2015

Majority of lung cancer treatment decisions are not guided by patient’s genetic makeup, according to new international survey

04.06.2015

FDA Files Supplemental New Drug Application for Boehringer Ingelheim’s Pradaxa® (dabigatran etexilate mesylate) for the Prophylaxis of Deep Venous Thrombosis and Pulmonary Embolism After Hip Replacement Surgery

03.23.2015

First-in-class type 2 diabetes treatment Glyxambi® (empagliflozin/linagliptin) tablets for adults now available in U.S. pharmacies

03.20.2015

Boehringer Ingelheim’s Investigational Biologic Cleared Skin Better than Ustekinumab in Head-to-Head Phase II Psoriasis Study

03.16.2015

New Data from Boehringer Ingelheim’s GLORIATM-AF Registry Show Non-Valvular Atrial Fibrillation (NVAF) Patients at High Risk of Stroke May Be Undertreated

03.14.2015

Boehringer Ingelheim Launches The 4Ward Coalition, a Multi-Disciplinary Collaboration Dedicated to Advancing Anticoagulation Care

03.02.2015

Boehringer Ingelheim Submits Biologics License Application to FDA for Idarucizumab*, Investigational Specific Reversal Agent for Pradaxa® (dabigatran etexilate mesylate)

02.21.2015

New Phase III Data in Asthma Patients Show Tiotropium Improves Lung Function, Regardless of Allergic Status

02.12.2015

New Survey Uncovers Emotional and Physical Impact of Idiopathic Pulmonary Fibrosis, a Fatal Lung Disease

back 1 2 3 4 5 6 7 8 9 10